Tokai Pharmaceuticals Revenue and Competitors

License our Company Data API

N/A

Total Funding

Estimated Revenue & Valuation

Tokai Pharmaceuticals's estimated annual revenue is currently $5.1M per year.(i)
Tokai Pharmaceuticals's estimated revenue per employee is $142,083

Employee Data

Tokai Pharmaceuticals has 36 Employees.(i)
Tokai Pharmaceuticals grew their employee count by 29% last year.

Tokai Pharmaceuticals's People

Name	Title	Email/Phone
1 John Herberger	VP, Technical Operations	Reveal Email/Phone
2 Carmen Mak	VP, Biometrics	Reveal Email/Phone
3 Marina Escudero	VP, Clinical Operations	Reveal Email/Phone
4 Steve Perrin	President and Chief Scientific Officer	Reveal Email/Phone
5 Bryan Smith	General Counsel, Chief Compliance Officer, & Corporate Secretary	Reveal Email/Phone
6 Paul Little	Chief Financial Officer	Reveal Email/Phone
7 Maeve McNally	Director Project Management	Reveal Email/Phone
8 David Hovland	Chief Regulatory Officer	Reveal Email/Phone
9 Shana Burns	Associate Director, Clinical Data Management	Reveal Email/Phone
10 Giselle Peschard	Medical Director, Clinical Development	Reveal Email/Phone

Tokai Pharmaceuticals Competitors & AlternativesAdd Company

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 DiaCarta	$4.4M	57	-8%	$53M	N/A
#2 Mission Bio	$21.2M	137	-26%	$110M	N/A
#3 Quadrants Scien...	$0.9M	5	0%	N/A	N/A
#4 Calcilytix Ther...	$2.3M	15	15%	N/A	N/A
#5 Ravata Solution...	$1.6M	4	-50%	N/A	N/A
#6 Range Biotechno...	$0.7M	8	0%	N/A	N/A
#7 Mission Barns	$11.5M	74	-12%	N/A	N/A
#8 Geron Corporati...	$0.4M	275	10%	$236.7M	N/A
#9 Mindstrong	$4M	51	-74%	$160M	N/A
#10 CalciMedica	$2.3M	17	31%	N/A	N/A

Add Company

Show More Biotech Companies

What Is Tokai Pharmaceuticals?

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.

keywords:N/A

N/A

Total Funding

Number of Employees

$5.1M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tokai Pharmaceuticals News

2022-04-13 - Evolving Role of Prostate-Specific Membrane Antigen ...

Honoraria: Research to Practice, Astellas Pharma, AstraZeneca, ... Janssen Oncology, Tokai Pharmaceuticals, Astellas Pharma, Incyte, Pfizer,...